Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. Ken Uchino, MD

Specialist Cleveland, OH Male

NPI: 1164498747

Total Payments

$7,605

2024 Payments

$143.38

Companies

Transactions

Medicare Patients

792

Medicare Billing

$78,893

Payment Breakdown by Category

Consulting$3,100 (40.8%)

Other$1,500 (19.7%)

Research$1,286 (16.9%)

Food & Beverage$922.51 (12.1%)

Travel$796.76 (10.5%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Consulting Fee	$3,100	1	40.8%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$1,500	2	19.7%
Unspecified	$1,286	12	16.9%
Food and Beverage	$922.51	7	12.1%
Travel and Lodging	$796.76	3	10.5%

Payments by Type

General

$6,319

13 transactions

Research

$1,286

12 transactions

Top Paying Companies

Company	Total	Records	Latest Year
Genentech, Inc.	$4,398	7	$0 (2022)
PORTOLA PHARMACEUTICALS, INC.	$1,399	3	$0 (2018)
Biogen, Inc.	$1,286	12	$0 (2018)
Stryker Corporation	$379.05	2	$0 (2018)
Bayer Healthcare Pharmaceuticals Inc.	$143.38	1	$0 (2024)

Payment History by Year

Year	Amount	Transactions	Top Company
2024	$143.38	1	Bayer Healthcare Pharmaceuticals Inc. ($143.38)
2022	$160.49	1	Genentech, Inc. ($160.49)
2018	$7,302	23	Genentech, Inc. ($4,238)

All Payment Transactions

25 individual payment records from CMS Open Payments

Date	Company	Product	Nature	Form	Amount	Type
07/10/2024	Bayer Healthcare Pharmaceuticals Inc.	—	Food and Beverage	In-kind items and services	$143.38	General
02/08/2022	Genentech, Inc.	—	Food and Beverage	In-kind items and services	$160.49	General
12/31/2018	Stryker Corporation	TREVO (Device)	Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	Cash or cash equivalent	$250.00	General
Category: MICROCATHETERSTENTRIEVER
11/02/2018	Stryker Corporation	TREVO (Device)	Food and Beverage	Cash or cash equivalent	$129.05	General
Category: MICROCATHETERSTENTRIEVER
10/18/2018	PORTOLA PHARMACEUTICALS, INC.	ANDEXXA (Drug)	Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	Cash or cash equivalent	$1,250.00	General
Category: HEMATOLOGY/NEUROLOGY
10/18/2018	PORTOLA PHARMACEUTICALS, INC.	ANDEXXA (Drug)	Food and Beverage	Cash or cash equivalent	$98.50	General
Category: HEMATOLOGY/NEUROLOGY
10/18/2018	PORTOLA PHARMACEUTICALS, INC.	ANDEXXA (Drug)	Travel and Lodging	Cash or cash equivalent	$50.00	General
Category: HEMATOLOGY/NEUROLOGY
10/17/2018	Genentech, Inc.	Activase (Biological)	Food and Beverage	In-kind items and services	$3.88	General
Category: Metabolism & Primary Care
09/07/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$61.47	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
09/07/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$58.99	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
09/07/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$40.10	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
09/07/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$29.84	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
09/06/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$133.00	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
09/06/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$64.84	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
09/06/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$59.69	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
09/06/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$59.10	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
09/05/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$302.26	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
09/05/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$286.41	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
09/05/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$134.97	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
09/05/2018	Biogen, Inc.	—	—	Cash or cash equivalent	$55.50	Research
Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
04/06/2018	Genentech, Inc.	Cathflo Activase (Biological)	Food and Beverage	In-kind items and services	$166.75	General
Category: Metabolism & Primary Care
04/05/2018	Genentech, Inc.	Cathflo Activase (Biological)	Consulting Fee	Cash or cash equivalent	$3,100.00	General
Category: Metabolism & Primary Care
04/05/2018	Genentech, Inc.	Cathflo Activase (Biological)	Travel and Lodging	In-kind items and services	$481.69	General
Category: Metabolism & Primary Care
04/05/2018	Genentech, Inc.	Cathflo Activase (Biological)	Travel and Lodging	In-kind items and services	$265.07	General
Category: Metabolism & Primary Care
04/05/2018	Genentech, Inc.	Cathflo Activase (Biological)	Food and Beverage	In-kind items and services	$220.46	General
Category: Metabolism & Primary Care

Research Studies & Clinical Trials

Study Name	Company	Amount	Records
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction	Biogen, Inc.	$1,286	12

Medicare Billing by Year

Year	Procedures	Beneficiaries	Services	Submitted	Medicare Paid
2023	10	185	217	$133,859	$17,643
2022	11	211	251	$136,459	$20,600
2021	10	230	282	$140,349	$23,389
2020	7	166	226	$108,626	$17,261

Total Patients

792

Total Services

976

Medicare Billing

$78,893

Procedure Codes

All Medicare Procedures & Services

38 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS	Description	Setting	Year	Patients	Services	Charges	Medicare Paid	Ratio
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	Facility	2023	20	33	$20,064	$3,023	15.1%
99215	Established patient office or other outpatient visit, 40-54 minutes	Facility	2023	23	27	$15,872	$2,833	17.8%
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	Facility	2023	24	25	$26,206	$2,406	9.2%
99205	New patient office or other outpatient visit, 60-74 minutes	Facility	2023	20	20	$16,972	$2,230	13.1%
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	Facility	2023	15	16	$16,884	$2,203	13.0%
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	Facility	2023	17	27	$11,448	$1,660	14.5%
99204	New patient office or other outpatient visit, 45-59 minutes	Facility	2023	11	11	$7,956	$1,127	14.2%
99214	Established patient office or other outpatient visit, 30-39 minutes	Facility	2023	15	17	$7,063	$1,122	15.9%
93880	Ultrasound of both sides of head and neck blood flow	Facility	2023	27	28	$8,092	$738.50	9.1%
99447	Telephone or internet assessment with verbal and written report by consulting physician, 11-20 minutes	Facility	2023	13	13	$3,302	$300.41	9.1%
99223	Initial hospital inpatient care per day, typically 70 minutes	Facility	2022	25	25	$25,550	$4,374	17.1%
99232	Follow-up hospital inpatient care per day, typically 25 minutes	Facility	2022	34	64	$24,640	$3,580	14.5%
99205	New patient office or other outpatient visit, 60-74 minutes	Facility	2022	19	19	$14,524	$2,630	18.1%
99222	Initial hospital inpatient care per day, typically 50 minutes	Facility	2022	24	24	$23,136	$2,515	10.9%
99215	Established patient office or other outpatient visit, 40-54 minutes	Facility	2022	20	23	$12,196	$2,308	18.9%
99233	Follow-up hospital inpatient care per day, typically 35 minutes	Facility	2022	11	17	$9,401	$1,342	14.3%
99204	New patient office or other outpatient visit, 45-59 minutes	Facility	2022	12	12	$8,124	$1,299	16.0%
93880	Ultrasound of both sides of head and neck blood flow	Facility	2022	32	33	$8,679	$952.01	11.0%
99214	Established patient office or other outpatient visit, 30-39 minutes	Facility	2022	11	11	$4,103	$762.78	18.6%
99238	Hospital discharge day management, 30 minutes or less	Facility	2022	12	12	$4,500	$691.30	15.4%
99446	Telephone or internet assessment with verbal and written report by consulting physician, 5-10 minutes	Facility	2022	11	11	$1,606	$145.69	9.1%
99232	Subsequent hospital inpatient care, typically 25 minutes per day	Facility	2021	44	87	$32,538	$4,891	15.0%
99223	Initial hospital inpatient care, typically 70 minutes per day	Facility	2021	28	28	$28,616	$4,786	16.7%
99205	New patient outpatient visit, total time 60-74 minutes	Facility	2021	23	23	$16,836	$3,331	19.8%
99215	Established patient outpatient visit, total time 40-54 minutes	Facility	2021	24	27	$13,917	$3,130	22.5%

1 2 »

About Dr. Ken Uchino, MD

Dr. Ken Uchino, MD is a Specialist healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164498747.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ken Uchino, MD has received a total of $7,605 in payments from pharmaceutical and medical device companies, with $143.38 received in 2024. These payments were reported across 25 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($3,100).

As a Medicare-enrolled provider, Uchino has provided services to 792 Medicare beneficiaries, totaling 976 services with total Medicare billing of $78,893. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty Specialist
Other Specialties Neurology, Vascular Neurology
Location Cleveland, OH
Active Since 02/24/2006
Last Updated 11/28/2022
Taxonomy Code 174400000X
Entity Type Individual
NPI Number 1164498747

Products in Payments

Cathflo Activase (Biological) $4,234
ANDEXXA (Drug) $1,399
TREVO (Device) $379.05
Activase (Biological) $3.88

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.